Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

被引：0
|
作者：
F. Pietrantonio
P. Biondani
M. Milione
F. Melotti
G. Bertarelli
F. Perrone
F. de Braud
L. Mariani
G. Fanetti
D. Cortinovis
M. Di Bartolomeo
机构：
[1] Fondazione IRCCS Istituto Nazionale Dei Tumori,Medical Oncology Unit 1, Medical Oncology Department
[2] Fondazione IRCCS Istituto Nazionale Tumori,Pathology Department
[3] Fondazione IRCCS Istituto Nazionale Tumori,Statistics and Biometry Unit
[4] A.O. San Gerardo,Medical Oncology Unit
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Bax; Colorectal cancer; Biomarkers; Chemotherapy; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：582 / 586
页数：4
相关论文
共 50 条
  • [21] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    Alliot, C
    Barrios, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (10) : 2050 - 2051
  • [22] Efficacy and Safety of Irinotecan-Based Chemotherapy for Advanced Colorectal Cancer outside Clinical Trials: An Observational Study
    Moehler, Markus
    Ababneh, Younes
    Verpoort, Karl
    Schmidt, Burghard
    Musch, Reinhard
    Soeling, Ulrike
    Maintz, Christoph
    Siebler, Juergen
    Schimanski, Carl C.
    Galle, Peter R.
    Fahlke, Joerg
    ONKOLOGIE, 2010, 33 (12): : 684 - 690
  • [23] Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy
    Yu, Qian-Qian
    Qiu, Hong
    Zhang, Ming-Sheng
    Hu, Guang-Yuan
    Liu, Bo
    Huang, Liu
    Liao, Xin
    Li, Qian-Xia
    Li, Zhi-Huan
    Yuan, Xiang-Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (16) : 4250 - 4258
  • [24] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    Aparicio, T
    Desramé, J
    Lecomte, T
    Mitry, E
    Belloc, J
    Etienney, I
    Montembault, S
    Vayre, L
    Locher, C
    Ezenfis, J
    Artru, P
    Mabro, M
    Dominguez, S
    BRITISH JOURNAL OF CANCER, 2003, 89 (08) : 1439 - 1444
  • [25] Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy
    Qian-Qian Yu
    Hong Qiu
    Ming-Sheng Zhang
    Guang-Yuan Hu
    Bo Liu
    Liu Huang
    Xin Liao
    Qian-Xia Li
    Zhi-Huan Li
    Xiang-Lin Yuan
    World Journal of Gastroenterology, 2016, (16) : 4250 - 4258
  • [26] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    T Aparicio
    J Desramé
    T Lecomte
    E Mitry
    J Belloc
    I Etienney
    S Montembault
    L Vayre
    C Locher
    J Ezenfis
    P Artru
    M Mabro
    S Dominguez
    British Journal of Cancer, 2003, 89 : 1439 - 1444
  • [27] Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer
    Cha, Yongjun
    Kim, Sun Young
    Yeo, Hyun Yang
    Baek, Ji Yeon
    Choi, Moon Ki
    Jung, Kyung Hae
    Dong, Seung Myung
    Chang, Hee Jin
    NEOPLASIA, 2019, 21 (01): : 146 - 155
  • [28] KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin- or irinotecan-based treatment
    Soeda, Hiroshi
    Shimodaira, Hideki
    Waianabe, Mika
    Suzuki, Takao
    Gamo, Makio
    Takahashi, Masanobu
    Komine, Keigo
    Kato, Shunsuke
    Ishioka, Chikashi
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 356 - 362
  • [29] Irinotecan in colorectal cancer in elderly patients with advanced colorectal cancer
    Sastre, J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S22 - S22
  • [30] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    C Alliot
    M Barrios
    British Journal of Cancer, 2004, 90 : 2050 - 2051
12345